Private sector COVID-19 vaccination service by Malaysian Genomics in collaboration with Pharmaniaga

Kuala Lumpur, 6 August 2021: Malaysian Genomics Resource Centre Berhad will collaborate with Malaysia’s largest integrated pharmaceutical group, Pharmaniaga Lifesciences Sdn Bhd, on the distribution and administration of COVID-19 vaccines to the private sector.

Malaysian Genomics will work with companies such as HealthMetrics Sdn Bhd, a third-party administrator, and other partners on the vaccination of private-sector employees. This effort is expected to commence in the second week of August 2021.

“Organisations with large workforces will be in a better position to protect their staff when they resume operations, as Malaysia looks toward a horizon of reopening all sectors. We are supporting the Government’s efforts to inject much-needed momentum into nationwide vaccination rates, in order to achieve herd immunity as early as possible,” said Chief Executive Officer, Sasha Nordin.

To support this initiative to speed up vaccinations among employees, Malaysian Genomics will procure Sinovac vaccines from Pharmaniaga Lifesciences. The administration of the vaccines will be executed through Malaysian Genomics’ network of clinical partners nationwide. Interested clinicians and corporates can find out more via [email protected].

Earlier this week, the company welcomed two notable individuals to its board as independent directors, retired Health Ministry Secretary-General Dato’ Seri Dr Chen Chaw Min and former Securities Commission board member Datuk Francis Tan Leh Kiah.

Dato’ Seri Dr Chen’s career in the Malaysian civil service spanned more than 30 years. At Malaysia’s Health Ministry, he contributed significantly to Malaysia’s COVID-19 response before retiring as its Secretary-General in February this year.

Datuk Francis Tan has a wealth of experience in corporate and tax matters, accumulated from over 35 years of working experience with both the Government and the private sector. He was the former managing partner of Azman, Davidson & Co. Advocates and Solicitors, and he served 20 years as a board member of the Securities Commission.

Malaysian Genomics shares closed at RM2.08 yesterday, 5 August, a new high for the company whose shares were at 0.55 sen exactly one year ago.

A pioneer in genome sequencing and analysis, Malaysian Genomics recently diversified into biopharmaceutical and healthcare services, including the provision of Chimeric Antigen Receptor T-cell (CAR T-cell) immunotherapy for cancers.

The company intends to obtain National Pharmaceutical Regulatory Agency (NPRA) accreditation for cell development and cell engineering through the Current Good Manufacturing Practice (cGMP) certification for its new laboratory located in Selangor. With the cGMP certification, Malaysian Genomics will have the first Biosafety Level 2 (BSL-2) laboratory in the country for cell therapy.

This content is provided by the Malaysian Genomics Resource Centre Berhad.

Interested in having your announcements on Malaysiakini? Contact the announcements team at [email protected] or WhatsApp on +60 17-323 0707 for urgent matters.